- Home
- ATAI vs SEG Comparison
ATAI vs SEG Comparison
Compare ATAI & SEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- SEG
- Stock Information
- Founded
- ATAI 2018
- SEG 2024
- Country
- ATAI Germany
- SEG United States
- Employees
- ATAI N/A
- SEG N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- SEG
- Sector
- ATAI Health Care
- SEG
- Exchange
- ATAI Nasdaq
- SEG NYSE
- Market Cap
- ATAI 291.5M
- SEG N/A
- IPO Year
- ATAI 2021
- SEG N/A
- Fundamental
- Price
- ATAI $1.24
- SEG $20.87
- Analyst Decision
- ATAI Strong Buy
- SEG
- Analyst Count
- ATAI 4
- SEG 0
- Target Price
- ATAI $9.00
- SEG N/A
- AVG Volume (30 Days)
- ATAI 1.7M
- SEG 133.1K
- Earning Date
- ATAI 03-17-2025
- SEG 05-05-2025
- Dividend Yield
- ATAI N/A
- SEG N/A
- EPS Growth
- ATAI N/A
- SEG N/A
- EPS
- ATAI N/A
- SEG N/A
- Revenue
- ATAI $308,000.00
- SEG $78,565,000.00
- Revenue This Year
- ATAI N/A
- SEG N/A
- Revenue Next Year
- ATAI $20.00
- SEG N/A
- P/E Ratio
- ATAI N/A
- SEG N/A
- Revenue Growth
- ATAI N/A
- SEG 9.05
- 52 Week Low
- ATAI $1.03
- SEG $19.54
- 52 Week High
- ATAI $2.85
- SEG $36.50
- Technical
- Relative Strength Index (RSI)
- ATAI 36.74
- SEG N/A
- Support Level
- ATAI $1.42
- SEG N/A
- Resistance Level
- ATAI $1.58
- SEG N/A
- Average True Range (ATR)
- ATAI 0.12
- SEG 0.00
- MACD
- ATAI -0.00
- SEG 0.00
- Stochastic Oscillator
- ATAI 4.55
- SEG 0.00
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.